Literature DB >> 10851319

MUC1 Expression in Prostate Carcinoma: Correlation with Grade and Stage.

.   

Abstract

Mucins have been implicated in the biologic behavior and progression of several types of cancer. The aims of this study were to define the expression pattern of one particular mucin, MUC1, in benign and malignant human prostate tissue and to determine if MUC1 expression correlates with tumor grade and stage. Immunohistochemical staining utilizing an anti-MUC1 monoclonal antibody was performed on 4 fetal prostates, 4 specimens of benign prostatic hyperplasia (BPH), and 34 radical prostatectomy specimens. In human fetal and BPH specimens, there was an apical pattern of MUC1 expression, similar to that reported in other normal and benign tissues. Ninety-four percent of the prostate cancers were MUC1 positive. A high percentage of prostate cancer specimens (62%) demonstrated a diffuse, cytoplasmic staining pattern. There was a statistically significant correlation between diffuse MUC1 staining and Gleason pattern, with a diffuse/total staining percentage of 9% in Gleason 2, 64% in Gleason 3, 80% in Gleason 4, and 100% in Gleason 5. More diffuse staining was also seen in samples from patients with high pathologic stage: 21% in T(2), 75% in T(3), and 67% in N(1) disease. These data indicate that MUC1 expression is prevalent in prostate cancer and that diffuse cytoplasmic staining correlates with advanced Gleason pattern and advanced pathologic stage.

Entities:  

Year:  1999        PMID: 10851319

Source DB:  PubMed          Journal:  Mol Urol        ISSN: 1091-5362


  21 in total

1.  Molecular Validation of PACE4 as a Target in Prostate Cancer.

Authors:  François D'Anjou; Sophie Routhier; Jean-Pierre Perreault; Alain Latil; David Bonnel; Isabelle Fournier; Michel Salzet; Robert Day
Journal:  Transl Oncol       Date:  2011-06-01       Impact factor: 4.243

2.  O-glycosylation of MUC1 mucin in prostate cancer and the effects of its expression on tumor growth in a prostate cancer xenograft model.

Authors:  Pushpa Premaratne; Karin Welén; Jan-Erik Damber; Gunnar C Hansson; Malin Bäckström
Journal:  Tumour Biol       Date:  2010-09-26

3.  MUC1 oncoprotein is a druggable target in human prostate cancer cells.

Authors:  Maya Datt Joshi; Rehan Ahmad; Li Yin; Deepak Raina; Hasan Rajabi; Glenn Bubley; Surender Kharbanda; Donald Kufe
Journal:  Mol Cancer Ther       Date:  2009-11-03       Impact factor: 6.261

4.  MUC1-C oncoprotein confers androgen-independent growth of human prostate cancer cells.

Authors:  Hasan Rajabi; Rehan Ahmad; Caining Jin; Maya Datt Joshi; Minakshi Guha; Maroof Alam; Surender Kharbanda; Donald Kufe
Journal:  Prostate       Date:  2012-04-02       Impact factor: 4.104

5.  Transmembrane mucins as novel therapeutic targets.

Authors:  Pamela E Constantinou; Brian P Danysh; Neeraja Dharmaraj; Daniel D Carson
Journal:  Expert Rev Endocrinol Metab       Date:  2011-11

Review 6.  Immunotherapy in prostate cancer: emerging strategies against a formidable foe.

Authors:  Marijo Bilusic; Christopher Heery; Ravi A Madan
Journal:  Vaccine       Date:  2011-07-07       Impact factor: 3.641

7.  MUC1 expression in pulmonary metastatic tumors: a comparison of primary lung cancer.

Authors:  Kyoichi Kaira; Takehiro Okumura; Kazuo Nakagawa; Yasuhisa Ohde; Toshiaki Takahashi; Haruyasu Murakami; Tateaki Naito; Masahiro Endo; Haruhiko Kondo; Takashi Nakajima; Nobuyuki Yamamoto
Journal:  Pathol Oncol Res       Date:  2011-10-02       Impact factor: 3.201

8.  MUC1 expression in thymic epithelial tumors: MUC1 may be useful marker as differential diagnosis between type B3 thymoma and thymic carcinoma.

Authors:  Kyoichi Kaira; Haruyasu Murakami; Masakuni Serizawa; Yasuhiro Koh; Masato Abe; Yasuhisa Ohde; Toshiaki Takahashi; Haruhiko Kondo; Takashi Nakajima; Nobuyuki Yamamoto
Journal:  Virchows Arch       Date:  2011-01-21       Impact factor: 4.064

9.  Defining aggressive prostate cancer using a 12-gene model.

Authors:  Tarek A Bismar; Francesca Demichelis; Alberto Riva; Robert Kim; Sooryanarayana Varambally; Le He; Jeff Kutok; Jonathan C Aster; Jeffery Tang; Rainer Kuefer; Matthias D Hofer; Phillip G Febbo; Arul M Chinnaiyan; Mark A Rubin
Journal:  Neoplasia       Date:  2006-01       Impact factor: 5.715

Review 10.  Prostate cancer relevant antigens and enzymes for targeted drug delivery.

Authors:  Ashutosh Barve; Wei Jin; Kun Cheng
Journal:  J Control Release       Date:  2014-05-27       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.